​

Collegium Pharmaceutical (COLL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

COLL Stock Forecast

Collegium Pharmaceutical (COLL) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $42.00, with a high of $50.00 and a low of $36.00. This represents a 36.76% increase from the last price of $30.71.

$25 $30 $35 $40 $45 $50 High: $50 Avg: $42 Low: $36 Last Closed Price: $30.71

COLL Stock Rating

Collegium Pharmaceutical stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (62.50%), 2 Hold (25.00%), 1 Sell (12.50%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 2 5 Strong Sell Sell Hold Buy Strong Buy

COLL Price Target Upside V Benchmarks

TypeNameUpside
StockCollegium Pharmaceutical36.76%
SectorHealthcare Stocks 25.00%
IndustrySpecialty & Generic Drug Manufacturers Stocks28.73%

Price Target Trends

1M3M12M
# Anlaysts127
Avg Price Target$36.00$38.00$41.86
Last Closing Price$30.71$30.71$30.71
Upside/Downside17.23%23.74%36.31%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25221--5
Jan, 25222--6
Dec, 24122--5
Nov, 24342--9
Oct, 24342--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 04, 2025David AmsellemPiper Sandler$36.00$30.9316.39%17.23%
Nov 11, 2024Glen SantangeloJefferies$40.00$32.1824.30%30.25%
Sep 04, 2024Oren LivnatH.C. Wainwright$50.00$38.6529.37%62.81%
Aug 09, 2024David AmsellemPiper Sandler$37.00$34.636.84%20.48%
Jul 30, 2024Oren LivnatH.C. Wainwright$47.00$38.6021.76%53.04%
Jun 07, 2024Glen SantangeloJefferies$44.00$31.3640.31%43.28%
May 10, 2024David AmsellemPiper Sandler$39.00$33.1117.79%26.99%
Jan 05, 2023Needham$35.00$26.9829.73%13.97%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 04, 2025Piper SandlerNeutralNeutralhold
Jan 10, 2025NeedhamBuyBuyupgrade
Nov 11, 2024JefferiesBuyBuyhold
Oct 11, 2024Piper SandlerNeutralNeutralhold
Sep 05, 2024SusquehannaNegativedowngrade
Sep 04, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024Piper SandlerNeutralNeutralhold
Jul 30, 2024H.C. WainwrightBuyupgrade
Jun 07, 2024JefferiesUnderperformBuyupgrade
May 10, 2024Sandler O'NeillBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-1 $3 $7 $11 $15 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.78$2.05$-0.74$1.60-----
Avg Forecast$3.75$3.84$4.33$5.21$6.18$6.64$7.29$6.87$11.06
High Forecast$3.65$3.73$4.18$5.11$6.07$6.02$6.08$6.80$10.94
Low Forecast$3.90$3.99$4.47$5.28$6.27$7.02$8.50$6.94$11.18
Surprise %-79.20%-46.61%-117.09%-69.29%-----

Revenue Forecast

$250M $360M $470M $580M $690M $800M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$310.02M$276.87M$463.93M$566.77M-----
Avg Forecast$311.22M$332.37M$459.50M$564.88M$629.25M$743.38M$754.36M$722.52M$702.30M
High Forecast$304.54M$325.23M$446.84M$563.21M$626.65M$737.07M$746.71M$703.29M$696.53M
Low Forecast$320.43M$342.21M$471.01M$565.79M$631.55M$749.26M$762.01M$741.74M$708.08M
Surprise %-0.39%-16.70%0.96%0.33%-----

Net Income Forecast

$-150M $-20M $110M $240M $370M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$26.75M$71.52M$-25.00M$48.16M-----
Avg Forecast$23.54M$54.01M$-81.41M$48.16M$257.86M$272.40M$304.59M$287.15M$462.18M
High Forecast$18.83M$20.76M$-103.95M$34.82M$253.68M$251.51M$254.10M$284.08M$457.24M
Low Forecast$28.24M$87.25M$-58.87M$61.49M$262.04M$293.29M$355.07M$290.22M$467.12M
Surprise %13.66%32.42%-69.29%------

COLL Forecast FAQ

Is Collegium Pharmaceutical stock a buy?

Collegium Pharmaceutical stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Collegium Pharmaceutical is a favorable investment for most analysts.

What is Collegium Pharmaceutical's price target?

Collegium Pharmaceutical's price target, set by 8 Wall Street analysts, averages $42 over the next 12 months. The price target range spans from $36 at the low end to $50 at the high end, suggesting a potential 36.76% change from the previous closing price of $30.71.

How does Collegium Pharmaceutical stock forecast compare to its benchmarks?

Collegium Pharmaceutical's stock forecast shows a 36.76% upside, outperforming the average forecast for the healthcare stocks sector (25.00%) and outperforming the specialty & generic drug manufacturers stocks industry (28.73%).

What is the breakdown of analyst ratings for Collegium Pharmaceutical over the past three months?

  • February 2025: 40.00% Strong Buy, 40.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 20.00% Strong Buy, 40.00% Buy, 40.00% Hold, 0% Sell, 0% Strong Sell.

What is Collegium Pharmaceutical’s EPS forecast?

Collegium Pharmaceutical's average annual EPS forecast for its fiscal year ending in December is $6.18 for 2024, a 286.25% increase from the reported $1.6 in 2023. The prediction for 2025 is $6.64, $7.29 for 2026, $6.87 for 2027, and $11.06 for 2028.

What is Collegium Pharmaceutical’s revenue forecast?

Collegium Pharmaceutical's average annual revenue forecast for its fiscal year ending in December is $629.25M for 2024, a 11.02% increase from the reported $566.77M in 2023. The forecast for 2025 is $743.38M, $754.36M for 2026, $722.52M for 2027, and $702.3M for 2028.

What is Collegium Pharmaceutical’s net income forecast?

For its fiscal year ending in December, Collegium Pharmaceutical's average annual net income forecast is $257.86M for 2024, reflecting an 435.47% increase from the reported $48.16M in 2023. The projection for 2025 is $272.4M, $304.59M for 2026, $287.15M for 2027, and $462.18M for 2028.